Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nondiabetic subjects

Estela Wajcberg, Yoshinori Miyazaki, Curtis L Triplitt, Eugenio Cersosimo, Ralph A Defronzo

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

OBJECTIVE - 1) To evaluate the effect of a single oral dose of hexyl-insulin monoconjugate 2 (HIM2) on the rate of whole-body glucose disposal (R d) and endogenous glucose production (EGP) in healthy nondiabetic subjects, 2) to examine the reproducibility of HIM2 on glucose metabolism, and 3) to compare the results obtained with HIM2 with those using a bioequivalent dose of subcutaneous lispro insulin. RESEARCH DESIGN AND METHODS - Six healthy subjects ([means ± SE] aged 31 ± 5 years and BMI 23.1 ± 3.9 kg/m 2) participated in four studies performed in random order on separate days. Subjects ingested a single dose of HIM2 (0.125, 0.5, and 0.75 mg/kg) or received subcutaneous lispro insulin (0.1 units/kg). Studies were performed with [3- 3H]glucose, and plasma glucose concentration was maintained at basal levels for 4 h with the euglycemic clamp technique. After 6 weeks, subjects participated in two repeat studies to examine the reproducibility of HIM2 (0.5 mg/kg) and lispro insulin (0.1 units/kg). RESULTS - Fasting plasma insulin (7 μ/ml) increased to a maximum of 102, 321, and 561 μU/ml at 60 min after all three HIM2 doses (0.125, 0.5, and 0.75 mg/kg, respectively). A dose-related decrease in basal EGP was observed as the HIM2 dosage was increased from 0 to 0.125 to 0.5 mg/kg (P < 0.05 vs. each preceding dose). Suppression of EGP was similar with the 0.5- and 0.75-mg/kg HIM2 doses. A dose-related stimulation of basal R d was observed as the HIM2 dosage was increased from 0 to 0.125 to 0.5 (P < 0.05 vs. each preceding dose) to 0.75 mg/kg (P < 0.10 vs. preceding dose). R d (0-240 min) was increased by 0.5 mg/kg oral HIM2 to a value similar to 0.1 units/kg lispro insulin. The 0.125-mg/kg HIM2 dose reduced EGP (0-240 min) to a value that was similar to 0.1 units/kg lispro insulin. The variability in the effect of HIM2 and lispro on R d (25 ± 7 vs. 27 ± 1%, respectively) and on suppression of EGP (19 ±1 vs. 19 ± 0.7%, respectively) was similar. CONCLUSIONS - Oral HIM2 suppresses EGP and increases tissue R d in a dose-dependent manner. The effects of HIM2 on EGP and R d persisted at 240 min, even though plasma insulin concentration had returned to basal levels. Oral HIM2 may provide an effective and reproducible means of controlling postprandial plasma glucose excursions in diabetic patients.

Original languageEnglish (US)
Pages (from-to)2868-2873
Number of pages6
JournalDiabetes Care
Volume27
Issue number12
DOIs
StatePublished - Dec 2004

Fingerprint

Oral Administration
Healthy Volunteers
Insulin Lispro
Glucose
hexyl-insulin monoconjugate 2
Insulin
Glucose Clamp Technique
Fasting
Research Design

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nondiabetic subjects. / Wajcberg, Estela; Miyazaki, Yoshinori; Triplitt, Curtis L; Cersosimo, Eugenio; Defronzo, Ralph A.

In: Diabetes Care, Vol. 27, No. 12, 12.2004, p. 2868-2873.

Research output: Contribution to journalArticle

@article{ac9c02346c444b0a97f024df6fc9de50,
title = "Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nondiabetic subjects",
abstract = "OBJECTIVE - 1) To evaluate the effect of a single oral dose of hexyl-insulin monoconjugate 2 (HIM2) on the rate of whole-body glucose disposal (R d) and endogenous glucose production (EGP) in healthy nondiabetic subjects, 2) to examine the reproducibility of HIM2 on glucose metabolism, and 3) to compare the results obtained with HIM2 with those using a bioequivalent dose of subcutaneous lispro insulin. RESEARCH DESIGN AND METHODS - Six healthy subjects ([means ± SE] aged 31 ± 5 years and BMI 23.1 ± 3.9 kg/m 2) participated in four studies performed in random order on separate days. Subjects ingested a single dose of HIM2 (0.125, 0.5, and 0.75 mg/kg) or received subcutaneous lispro insulin (0.1 units/kg). Studies were performed with [3- 3H]glucose, and plasma glucose concentration was maintained at basal levels for 4 h with the euglycemic clamp technique. After 6 weeks, subjects participated in two repeat studies to examine the reproducibility of HIM2 (0.5 mg/kg) and lispro insulin (0.1 units/kg). RESULTS - Fasting plasma insulin (7 μ/ml) increased to a maximum of 102, 321, and 561 μU/ml at 60 min after all three HIM2 doses (0.125, 0.5, and 0.75 mg/kg, respectively). A dose-related decrease in basal EGP was observed as the HIM2 dosage was increased from 0 to 0.125 to 0.5 mg/kg (P < 0.05 vs. each preceding dose). Suppression of EGP was similar with the 0.5- and 0.75-mg/kg HIM2 doses. A dose-related stimulation of basal R d was observed as the HIM2 dosage was increased from 0 to 0.125 to 0.5 (P < 0.05 vs. each preceding dose) to 0.75 mg/kg (P < 0.10 vs. preceding dose). R d (0-240 min) was increased by 0.5 mg/kg oral HIM2 to a value similar to 0.1 units/kg lispro insulin. The 0.125-mg/kg HIM2 dose reduced EGP (0-240 min) to a value that was similar to 0.1 units/kg lispro insulin. The variability in the effect of HIM2 and lispro on R d (25 ± 7 vs. 27 ± 1{\%}, respectively) and on suppression of EGP (19 ±1 vs. 19 ± 0.7{\%}, respectively) was similar. CONCLUSIONS - Oral HIM2 suppresses EGP and increases tissue R d in a dose-dependent manner. The effects of HIM2 on EGP and R d persisted at 240 min, even though plasma insulin concentration had returned to basal levels. Oral HIM2 may provide an effective and reproducible means of controlling postprandial plasma glucose excursions in diabetic patients.",
author = "Estela Wajcberg and Yoshinori Miyazaki and Triplitt, {Curtis L} and Eugenio Cersosimo and Defronzo, {Ralph A}",
year = "2004",
month = "12",
doi = "10.2337/diacare.27.12.2868",
language = "English (US)",
volume = "27",
pages = "2868--2873",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "12",

}

TY - JOUR

T1 - Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nondiabetic subjects

AU - Wajcberg, Estela

AU - Miyazaki, Yoshinori

AU - Triplitt, Curtis L

AU - Cersosimo, Eugenio

AU - Defronzo, Ralph A

PY - 2004/12

Y1 - 2004/12

N2 - OBJECTIVE - 1) To evaluate the effect of a single oral dose of hexyl-insulin monoconjugate 2 (HIM2) on the rate of whole-body glucose disposal (R d) and endogenous glucose production (EGP) in healthy nondiabetic subjects, 2) to examine the reproducibility of HIM2 on glucose metabolism, and 3) to compare the results obtained with HIM2 with those using a bioequivalent dose of subcutaneous lispro insulin. RESEARCH DESIGN AND METHODS - Six healthy subjects ([means ± SE] aged 31 ± 5 years and BMI 23.1 ± 3.9 kg/m 2) participated in four studies performed in random order on separate days. Subjects ingested a single dose of HIM2 (0.125, 0.5, and 0.75 mg/kg) or received subcutaneous lispro insulin (0.1 units/kg). Studies were performed with [3- 3H]glucose, and plasma glucose concentration was maintained at basal levels for 4 h with the euglycemic clamp technique. After 6 weeks, subjects participated in two repeat studies to examine the reproducibility of HIM2 (0.5 mg/kg) and lispro insulin (0.1 units/kg). RESULTS - Fasting plasma insulin (7 μ/ml) increased to a maximum of 102, 321, and 561 μU/ml at 60 min after all three HIM2 doses (0.125, 0.5, and 0.75 mg/kg, respectively). A dose-related decrease in basal EGP was observed as the HIM2 dosage was increased from 0 to 0.125 to 0.5 mg/kg (P < 0.05 vs. each preceding dose). Suppression of EGP was similar with the 0.5- and 0.75-mg/kg HIM2 doses. A dose-related stimulation of basal R d was observed as the HIM2 dosage was increased from 0 to 0.125 to 0.5 (P < 0.05 vs. each preceding dose) to 0.75 mg/kg (P < 0.10 vs. preceding dose). R d (0-240 min) was increased by 0.5 mg/kg oral HIM2 to a value similar to 0.1 units/kg lispro insulin. The 0.125-mg/kg HIM2 dose reduced EGP (0-240 min) to a value that was similar to 0.1 units/kg lispro insulin. The variability in the effect of HIM2 and lispro on R d (25 ± 7 vs. 27 ± 1%, respectively) and on suppression of EGP (19 ±1 vs. 19 ± 0.7%, respectively) was similar. CONCLUSIONS - Oral HIM2 suppresses EGP and increases tissue R d in a dose-dependent manner. The effects of HIM2 on EGP and R d persisted at 240 min, even though plasma insulin concentration had returned to basal levels. Oral HIM2 may provide an effective and reproducible means of controlling postprandial plasma glucose excursions in diabetic patients.

AB - OBJECTIVE - 1) To evaluate the effect of a single oral dose of hexyl-insulin monoconjugate 2 (HIM2) on the rate of whole-body glucose disposal (R d) and endogenous glucose production (EGP) in healthy nondiabetic subjects, 2) to examine the reproducibility of HIM2 on glucose metabolism, and 3) to compare the results obtained with HIM2 with those using a bioequivalent dose of subcutaneous lispro insulin. RESEARCH DESIGN AND METHODS - Six healthy subjects ([means ± SE] aged 31 ± 5 years and BMI 23.1 ± 3.9 kg/m 2) participated in four studies performed in random order on separate days. Subjects ingested a single dose of HIM2 (0.125, 0.5, and 0.75 mg/kg) or received subcutaneous lispro insulin (0.1 units/kg). Studies were performed with [3- 3H]glucose, and plasma glucose concentration was maintained at basal levels for 4 h with the euglycemic clamp technique. After 6 weeks, subjects participated in two repeat studies to examine the reproducibility of HIM2 (0.5 mg/kg) and lispro insulin (0.1 units/kg). RESULTS - Fasting plasma insulin (7 μ/ml) increased to a maximum of 102, 321, and 561 μU/ml at 60 min after all three HIM2 doses (0.125, 0.5, and 0.75 mg/kg, respectively). A dose-related decrease in basal EGP was observed as the HIM2 dosage was increased from 0 to 0.125 to 0.5 mg/kg (P < 0.05 vs. each preceding dose). Suppression of EGP was similar with the 0.5- and 0.75-mg/kg HIM2 doses. A dose-related stimulation of basal R d was observed as the HIM2 dosage was increased from 0 to 0.125 to 0.5 (P < 0.05 vs. each preceding dose) to 0.75 mg/kg (P < 0.10 vs. preceding dose). R d (0-240 min) was increased by 0.5 mg/kg oral HIM2 to a value similar to 0.1 units/kg lispro insulin. The 0.125-mg/kg HIM2 dose reduced EGP (0-240 min) to a value that was similar to 0.1 units/kg lispro insulin. The variability in the effect of HIM2 and lispro on R d (25 ± 7 vs. 27 ± 1%, respectively) and on suppression of EGP (19 ±1 vs. 19 ± 0.7%, respectively) was similar. CONCLUSIONS - Oral HIM2 suppresses EGP and increases tissue R d in a dose-dependent manner. The effects of HIM2 on EGP and R d persisted at 240 min, even though plasma insulin concentration had returned to basal levels. Oral HIM2 may provide an effective and reproducible means of controlling postprandial plasma glucose excursions in diabetic patients.

UR - http://www.scopus.com/inward/record.url?scp=9444230519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9444230519&partnerID=8YFLogxK

U2 - 10.2337/diacare.27.12.2868

DO - 10.2337/diacare.27.12.2868

M3 - Article

VL - 27

SP - 2868

EP - 2873

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 12

ER -